medigraphic.com
ISSN 1684-1824 (Electronic)

2020, Number 6

<< Back Next >>

Rev Méd Electrón 2020; 42 (6)

Dexketoprofen plus pamabrom versus acetaminophen in primary dysmenorrhea: a controlled, randomized, double-blind, multicenter study

Guayasami LI, Rivera OV, González FY, Campoverde AJ, Contreras US, Reyes PR, Córdova CC

Language: Spanish
References: 18
Page:
PDF size: 389.19 Kb.


ABSTRACT

Background: It is known that plasma concentrations of antidiuretic hormone or vasopressin are higher in women with primary dysmenorrhea (DiPr) and could cause water retention with concomitant signs and symptoms that aggravate the illness. Monotherapy with NSAIDs sometimes achieves only partial relief because it does not affect vasopressin.
Objective: The aim was to evaluate the efficacy and tolerability of dexketoprofen + pamabrom in DiPr taking as reference acetaminophen.
Materials and methods: Double-blind, controlled, randomized study in patients with DiPr random to 1) Case group (PD): dexketoprofen + pamabrom or 2) Control group (CA): acetaminophen. The evolution of pain intensity, pain relief, severity of other present symptoms and overall satisfaction of the doctor and patient were evaluated. Adverse reactions were recorded.
Results: 172 patients were randomized, 86 in each group. The decrease in pain intensity, accompanying symptoms and pain relief evaluated by VAS, PID, SPID, PAR and TOTPAR respectively is significantly greater and faster at all times for the combination DP. Adverse reactions were minimal. The overall satisfaction of patients and doctors regarding treatment is significant in favor of the DP combination.
Conclusions: Dexketoprofen + pamabrom is significantly more effective and faster in the control of pain and other symptoms present in primary dysmenorrhea than acetaminophen demonstrating the validity of adding a mild diuretic to an NSAID to increase its effectiveness. DP treatment is well tolerated.


REFERENCES

  1. Lay-panel L, Debaina E, Sauvanetab E, et al. Del síntoma al diagnóstico. Dismenorrea. EMC - Tratado de Medicina. [Internet]. 2017 [citado 18/10/2019]; 21 (1): 1-5. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1636541016818000

  2. Morgan-Ortiz F, Morgan-Ruiz F, Báez-Barraza J, et al. Dismenorrea: una revisión. Rev Med UAS [Internet]. 2015 [citado 18/10/2019]; 5(1):29-42. Disponible en: Disponible en: http://hospital.uas.edu.mx/revmeduas/pdf/v5/n1/dismenorrea.pdf

  3. Ortiz MI. Eficacia de un programa fisioterapéutico para la atención de dismenorrea primaria. Revista Mexicana de Investigación en Cultura Física y Deporte [Internet]. 2016 [citado 18/10/2019]; 7(9):1-18. Disponible en: Disponible en: http://ened.conade.gob.mx/Documentos/REVISTA%20ENED/Revista9/articulo1.pdf

  4. López Méndez C, Girón Damas P, Molina Gómez MC, et al. Efectividad de la Fisioterapia en la dismenorrea primaria. Revisión sistemática. Cuestiones de fisioterapia. Revista Universitaria de Información e Investigación en Fisioterapia [Internet]. 2020 [citado 18/10/2019]; 49(3): 36-40 Disponible en: Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7562464

  5. Brouard R, Bossmar T, Fournié-Lloret D, et al. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea. BJOG [Internet]. 2000 [citado 18/10/2019]; 107(5):614-9. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10826575

  6. Strömberg P, Akerlund M, Forsling ML, et al. Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea. Acta Obstet Gynecol Scand [Internet]. 1984 [citado 18/10/2019]; 63(6):533-8. Disponible en:DOI: https://doi.org/10.3109/00016348409156715

  7. Muñoz Cedeño P K, Camacho Desiderio JE, Alvarado Chiquito O, et al. La dismenorrea como principal causante de periodos menstruales doloroso. RECIAMUC [Internet].2019[citado 18/10/2019]; 3(3): 769-788. Disponible en: Disponible en: https://doi.org/10.26820/reciamuc/3.(3).julio.2019.769-788

  8. Marjoribanks J, Ayeleke RO, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev [Internet]. 2015 [citado 18/10/2019]; 30(7):CD001751. Disponible en: DOI: https://doi.org/10.1002/14651858.CD001751.pub3

  9. Hanna M, Moon JY. A review of dexketoprofen trometamol in acute pain. Curr Med Res Opin [Internet]. 2018 [citado 18/10/2019]; 35(2):189-202. Disponible en DOI: Disponible en DOI: https://doi.org/10.1080/03007995.2018.1457016

  10. Ezcurdia M1, Cortejoso FJ, Lanzón R, et al. Comparison of the Efficacy and Tolerability of Dexketoprofen and Ketoprofen in the Treatment of Primary Dysmenorrhea. J Clin Pharmacol [Internet]. 1998 [citado 18/10/2019]; 38(S1):65S-73S. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/9882084

  11. Lucio-Maldonado S, Cruz-Salinas MA, López-Bojórquez E, et al. Bioanalytical Method for Pamabrom (Determined as 8-Bromotheophylline) and its Application to a Pharmacokinetic Study. J Bioequiv Stud [Internet]. 2017 [citado 18/10/2019]; 3(1): 101. Disponible en: DOI: http://doi.org//10.15744/2575-551x.3.101

  12. Núñez-Claudel B, Cáceres-Matos R, Vázquez-Santiago S, et al. Consecuencias de la dismenorrea primaria en adolescentes y mujeres. Revisión Sistemática Exploratoria [Internet]. 2020[citado: 18/10/2019];(3):132-147. https://doi.org/10.6018/iqual.402211

  13. Patil MV, Kolekar GB. Binding of Drug Pamabrom to Human Hemoglobin: Structural and Thermodynamic Characterization Studies. IJSR [Internet]. 2014 [citado 18/10/2019]; 3(11): 3095-3109. Disponible en: Disponible en: https://pdfs.semanticscholar.org/9f8b/b74dd28b46ba709b51fc33256980baa4885d.pdf

  14. Serinken M, Eken C, Karcıoğlu Ö. Intravenous Dexketoprofen versus Intravenous Paracetamol for Dysmenorrhea: A Randomized Controlled Trial. Balkan Med J [Internet]. 2018 [citado 18/10/2019]; 35(4):301-305. Disponible en: DOI: https://doi.org/10.4274/balkanmedj.2016.0536

  15. Núñez-Claudel B, Cáceres-Matos R, Vázquez-Santiago S, et al. Consecuencias de la dismenorrea primaria en adolescentes y mujeres. Revisión Sistemática Exploratoria . IQual. Revista De Género E Igualdad[Internet]. 2020[citado 18/10/2019] ;3: 132-147. Disponible en: Disponible en: https://doi.org/10.6018/iqual.402211

  16. Ali Z, Burnett I, Eccles R, et al. Efficacy of a paracetamol and caffeine combination in the treatment of the key symptoms of primary dysmenorrhea. Curr Med Res Opin [Internet]. 2007 [citado 18/10/2019]; 23(4):841-51.Disonible en: DOI: http://doi.org/10.1185/030079907x182239

  17. Di-Girolamo G, Sánchez AJ, De-Los-Santos AR, et al. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea? Expert Opin Pharmacother [Internet]. 2004 [citado: 18/10/2019]; 5(3):561-70. Disponible en DOI: https://doi.org/10.1517/14656566.5.3.561

  18. Ortiz M, Murguía-Cánovas G, Vargas-López LC, et al. Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial; Medwave [Internet]. 2016 [citado: 18/10/2019]; 16(9): e6587. Disponible en: DOI: http://doi.org./10.5867/medwave.2016.09.6587




2020     |     www.medigraphic.com